Mark S Segal, MD, PhD - Research

Research at a glance

Top areas of exploration

Cells, Cultured , 19 publications
Biomarkers , 17 publications
Kidney Failure, Chronic , 16 publications
Hypertension , 16 publications

Research activity

161 publications

10,466 citations

Why is this important?

Active clinical trials

HyperQure RDN System

HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant鈥�

Investigator: Mark S Segal
Status: Accepting Candidates
Ages: 22 Years - 80 Years
Sexes: All

EASi-KIDNEY

Investigator: Mark S Segal
Status: Accepting Candidates

REGEN-006

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with鈥�

Investigator: Mark S Segal
Status: Accepting Candidates
Ages: 30 Years - 80 Years
Sexes: All

My publications

161 publications

2015

Cost and Mortality Associated With Postoperative Acute Kidney Injury.

Annals of surgery

鈥�

2015

DNA Aptamer Assembly as a Vascular Endothelial Growth Factor Receptor Agonist.

Nucleic acid therapeutics

鈥�

2015

Fiber supplementation lowers plasma p-cresol in chronic kidney disease patients.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

鈥�

2015

Heart failure and chronic kidney disease: should we use spironolactone?

The American journal of the medical sciences

鈥�

2015

Higher levels of adiponectin in vascular endothelial cells are associated with greater brachial artery flow-mediated dilation in older adults.

Experimental gerontology

鈥�

网红黑料